ArticlePloS one2025
Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corona Virus Disease (COVID-19) has become a global public health crisis, and the Omicron variant has rapidly taken over as soon as it was detected Serum circulating metabolites can provide extensive insights into the pathogenesis and diagnosis of many diseases. We included 336 omicron variant cases (OC), 216 recovered cases (RC), and 380 healthy controls (HC) for untargeted metabolomics analysis and analyzed their serum metabolic profiles by liquid chromatography-tandem mass spectrometry. Principal component analysis, orthogonal partial least squares discriminant analysis, t-test analysis and false discovery rate were used to characterize the serum metabolites of OC and RC. In addition, a noninvasive diagnostic model for OC was developed using Receiver operating characteristic analysis. Finally, a correlation analysis was performed using data from our published articles. The results showed that compared with HC, five metabolites, including DL-stachydrine, D-(+)-pipecolinic acid, furazolidone, L-arginine and 5α-dihydrotestosterone glucuronide were significantly elevated and one metabolite, prenylcysteine, was significantly decreased in the serum of OC, and that the increase in L-arginine and the decrease in prenylcysteine led to impaired urea cycling and a high risk of developing atherosclerosis, respectively. These metabolites were not fully restored to healthy human levels in recovered cases. In addition, we constructed a noninvasive diagnostic model for distinguishing Omicron variant patients from healthy individuals based on the six differential metabolites, and achieved high diagnostic efficacy in both the discovery and validation cohorts. Finally, the results of the correlation analysis showed a strong correlation between the alterations in the oropharyngeal microbiome and serum metabolome and the clinical indicators in the omicron variant cases. This study was the first to characterize serum metabolites in OC and RC based on a large clinical cohort, and successfully constructed and validated a noninvasive diagnostic model for Omicron variant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.